Deutsche Bank raised the firm’s price target on Denali Therapeutics (DNLI) to $35 from $26 and keeps a Buy rating on the shares. The firm says the approval of Avlayah validates the company’s platform.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics price target raised to $42 from $32 at H.C. Wainwright
- Denali Therapeutics price target raised to $42 from $40 at Morgan Stanley
- Denali Therapeutics price target raised to $31 from $29 at BofA
- Denali Therapeutics price target raised to $41 from $34 at Stifel
- Denali Therapeutics price target raised to $32 from $29 at Baird